Replies to post #6232 on GTC Biotherapeutics (fka GTCB)

[dodah_2]

I bought a small amount at .87. I'm surprised that Pharming's drug was not approved, especially considering the positive press releases about Rhucin's progress. I believe it's PPs has been higher than GTCB's, in part, because of GTCB's previous approval, and its stockholders imagined approval would be fairly routine. In some respects it's nice to know the EMEA was not biased towards a European submission.

[croumagnon]

Sorry, I forgot about that earlier post. However, if you quote the full sentence instead of parsing it, you will see that I did not plan on selling below $0.9, namely:

"Below $0.9, selling GTCB currently does not make sense because they have other blockbusters in their pipeline besides ATryn and I presume the chance of good top line data is better than 50/50 although the selling lately is worrisome"

At any rate, as I clarified in following posts, I only sold 26,000 shares a couple of days ago at $0.92 and I bought them back plus some today at $0.89...

I am still worried but I think this is a steal below $0.9...

[jessellivermore]

Good... I'l probably be buying them.

I do not understand why people hate us. When nobody wants their shares, we buy them. When they must have more we sell them ours[i/].

Baron Rothchild